From Genryo’s Sidewinder technology to the Festival of Genomics & Biodata in the UK earlier this year – AI might be trending, ...

The agreement with Sino Bio, via its subsidiary Chia Tai Tianqing Pharma (CTTQ), allies GSK with a company that is one of ...

Novo Nordisk is running other phase 2 trials of the drug, including the 8212-Preserved study in heart failure with preserved ...

Partner Therapeutics' Bizengri has been approved for a new indication, a rare form of bile duct cancer, just two days after ...

Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion. Already a giant in the ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks. The ...

Swiss biotech Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of encouraging phase 2 data. The Zug-based company said ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US ...

The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the ...